Drug Trial Radar · NCT00093795
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,894
Actual
Start
Oct 2004
Primary completion
Mar 2012
Study completion Jun 2016
Sponsor
- Lead sponsor
- NSABP Foundation IncResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Conditions
- Breast Cancer
Interventions
CyclophosphamideDrug
Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
DocetaxelDrug
75 mg/m2 IV every 21 days for 6 cycles
GemcitabineDrug
2000 mg/m2 IV every 14 days for 4 cycles
PaclitaxelDrug
175 mg/m2 IV every 14 days for 4 cycles
DoxorubicinDrug
Group 1: 50 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary CancerTime frame: 5 years
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama
Providence Cancer Center
Anchorage, Alaska
Robert and Carol Weissman Cancer Center at Martin Memorial
Stuart, Florida
Lucille P. Markey Cancer Center at University of Kentucky
Lexington, Kentucky
South Shore Hospital
South Weymouth, Massachusetts
Methodist Estabrook Cancer Center
Omaha, Nebraska
CCOP - Northern New Jersey
Hackensack, New Jersey
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio
Chestnut Hill Healthcare Cancer Center
Philadelphia, Pennsylvania
Madigan Army Medical Center - Tacoma
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.